The PI3K/Akt inhibitor Ly 294,002, but not the ERK inhibitor PD 98059, inhibits the EGF-stimulated increase in m-SREBP-1 and FASN protein levels in MDA-MB-231 human breast cancer cells [24]. Here, SREBF1 is linked to breast carcinoma.